Panelists discuss the management of neurofibromatosis type 1 across pediatric and adult populations, focusing on both clinical and practical considerations. Panelists review the efficacy and safety of available therapies and share insights on how these treatments are being integrated into clinical practice.
Experts discuss the efficacy, safety, and long-term management of anti-CD20 therapies in relapsing multiple sclerosis (MS), including considerations for therapy de-escalation and switching, while emphasizing patient-centered factors and emerging strategies that may influence future MS treatment approaches.
M. Scott Perry, MD, and James Wheless, BScPharm, MD, FAAP, FACP, FAAN, FAES, FCNS, discuss how early genetic testing for SCN1A variants enables prompt diagnosis of Dravet syndrome, allowing clinicians to optimize treatment with newer targeted therapies such as stiripentol, fenfluramine, and cannabidiol, while avoiding contraindicated sodium channel blockers to improve seizure control and long-term outcomes.
W. Chris Winter, MD, and Margaret Park, MD, discuss how excessive daytime sleepiness in patients with obstructive sleep apnea is often underdiagnosed due to cultural normalization of fatigue and patient rationalization of symptoms, requiring clinicians to actively screen for sleepiness as a vital sign and consider FDA-approved wake-promoting medications like modafinil, armodafinil, and solriamfetol for those with residual sleepiness despite effective continuous positive airway pressure therapy.
Daniel Kremens, MD, JD; and Robert Hauser, MD, MBA, discuss how recent advancements in Parkinson disease therapies, including new extended-release formulations and subcutaneous pumps, may impact dyskinesia management, while exploring treatment strategies for patients with troublesome dyskinesia through clinical case examples.
Experts discuss the importance of early diagnosis in Alzheimer disease, and discuss the safety and efficacy of newer treatment options for mild cognitive impairment.
Gabriel Pardo, MD, and Martin Belkin, DO, discuss how multiple sclerosis (MS) management now centers on detecting and mitigating progression independent of relapse activity (PIRA) through advanced biomarkers, early intervention, and personalized high-efficacy therapies targeting neurological preservation.
Experts provide their clinical experience on identifying and managing smouldering multiple sclerosis, discussing the current treatment landscape and emerging approaches.
Neurology experts discuss how patients with multiple sclerosis (MS) acquire disability and the concept of progression independent of relapse activity (PIRA). They also share recommendations on how to evaluate and care for cognitive decline and disease progression in patients with MS.
Experts in neurology discuss the use of oral therapies in the treatment of relapsing-remitting multiple sclerosis (MS). They discuss treatment selection based on long-term and real-world data and how recent and emerging therapies will change the management of patients with relapsing-remitting MS.
Advanced practice practitioners discuss the co-occurrence of sleep disorders with other health conditions, patient awareness, and the importance of screening for sleep disorders. They also discuss the treatment landscape of insomnia and the use of dual orexin receptor antagonists in the management of insomnia.
Experts in neurology share considerations for the management of ethnically diverse and underrepresented populations including those of reproductive age.
Expert neurologists review updates in the management of Myasthenia Gravis.
Two multiple sclerosis experts discuss long-term and real-world data with oral therapies in the treatment of relapsing-remitting multiple sclerosis (RRMS) that was presented at ACTRIMS 2022.
Experts in sleep medicine provide key insights on a series of patient cases and evaluate the use of novel agents in the treatment landscape for narcolepsy.
Expert neurologists examine strategies for optimizing treatment formulations in the management of OFF episodes in Parkinson disease and highlight the importance of patient education.
Recommendations to neurologists on appropriately prescribing and managing patients with relapsing-remitting multiple sclerosis using novel, oral therapies.
Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, discuss the rare pediatric epilepsy conditions Dravet syndrome and Lennox-Gastaut syndrome, from prevalence to the approval of new therapies.
Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss the diagnosis, management, and treatment of Dravet Syndrome.
Experts in the diagnosis and treatment of Alzheimer disease discuss the recent approval of aducanumab, its implications on the field, and other promising therapies and diagnostic technologies in development.
Elizabeth Thiele, MD, PhD, and Peter Crino, MD, PhD, discuss the diagnosis and management of tuberous sclerosis complex (TSC) as well as unmet needs in the field.
Vamshi K. Rao, MD, and Eric P. Hoffman, PhD, discuss how dystrophin relates to Duchenne Muscular Dystrophy, current approved therapies, and treatments in development.
A discussion regarding the stigma associated with migraine and the importance of empowering patients and health care professionals to become involved in migraine advocacy.
Experts in neurology Laxman Bahroo, DO and Mindy K. Bixby, DO share insights into the diagnosis, management, and treatment of OFF episodes in Parkinson’s disease and highlight key therapeutic options currently available and in development.
Phyllis Zee, MD, PhD, and Alon Avidan, MD, MPH, provide an overview of behavioral and pharmacological approaches to the management of excessive daytime sleepiness (EDS) and narcolepsy and discuss the recent approval of agents with new mechanisms of action.
Experts review the challenges of managing OFF episodes in Parkinson's disease and the current treatment options to optimize therapy.
